Free Trial
→ Gold Hits New Highs as Global Markets Spiral (From Premier Gold Co) (Ad) Buy NVCR Stock  Free NVCR Stock Alerts

NovoCure (NVCR) Financials

NovoCure logo
$19.37 +0.19 (+0.99%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$19.56 +0.18 (+0.96%)
As of 09:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for NovoCure

Annual Income Statements for NovoCure

This table shows NovoCure's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Income / (Loss) Attributable to Common Shareholders		 -169 -207 -93 -58 20 -7.23 -64 -62 -132 -112 -81
Consolidated Net Income / (Loss)		 -169 -207 -93 -58 20 -7.23 -64 -62 -132 -112 -81
Net Income / (Loss) Continuing Operations		 -169 -207 -93 -58 20 -7.23 -64 -62 -132 -112 -81
Total Pre-Tax Income 		-131 -192 -82 -52 18 -8.82 -46 -48 -121 -107 -80
Total Operating Income		 -170 -233 -90 -44 30 -0.91 -34 -39 -115 -104 -80
Total Gross Profit		 468 381 423 420 388 263 168 121 37 12 5.45
Total Revenue		 605 509 538 535 494 351 248 177 83 33 15
Operating Revenue		 605 509 538 535 494 351 248 177 83 33 15
Total Cost of Revenue		 137 128 115 115 107 89 80 56 46 21 10
Operating Cost of Revenue		 137 128 115 115 107 89 80 56 40 21 10
Total Operating Expenses		 639 614 512 464 357 264 202 161 152 116 86
Selling, General & Admin Expense		 190 164 133 126 107 88 73 59 51 34 24
Marketing Expense		 239 227 174 137 118 97 78 64 59 39 21
Research & Development Expense		 210 223 206 201 132 79 51 38 41 44 40
Total Other Income / (Expense), net		 39 41 7.68 -7.74 -12 -7.91 -12 -9.17 -6.15 -3.15 -0.14
Interest & Investment Income		 39 41 7.68 -7.74 -12 - - - - - -
Income Tax Expense		 37 15 11 6.28 -1.71 -1.59 18 13 10 4.43 0.38
Basic Earnings per Share		 ($1.56) ($1.95) ($0.88) ($0.56) $0.20 ($0.07) ($0.69) ($0.70) ($1.54) ($3.67) ($6.46)
Weighted Average Basic Shares Outstanding		 107.83M 106.39M 104.66M 103.43M 100.93M 97.24M 91.83M 88.55M 85.56M 30.40M 12.49M
Diluted Earnings per Share		 ($1.56) ($1.95) ($0.88) ($0.56) $0.18 ($0.07) ($0.69) ($0.70) ($1.54) ($3.67) ($6.46)
Weighted Average Diluted Shares Outstanding		 107.83M 106.39M 104.66M 103.43M 108.88M 97.24M 91.83M 88.55M 85.56M 30.40M 12.49M
Weighted Average Basic & Diluted Shares Outstanding		 109.92M 107.09M 105.46M 104.42M 102.41M 97.24M 91.83M 88.55M 85.56M 30.40M 12.49M

Quarterly Income Statements for NovoCure

This table shows NovoCure's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -34 -66 -31 -33 -39 -47 -49 -57 -53 -37 -27
Consolidated Net Income / (Loss)		 -34 -66 -31 -33 -39 -47 -49 -57 -53 -37 -27
Net Income / (Loss) Continuing Operations		 -34 -66 -31 -33 -39 -47 -49 -57 -53 -37 -27
Total Pre-Tax Income 		-30 -55 -22 -23 -32 -39 -48 -54 -51 -33 -23
Total Operating Income		 -38 -63 -32 -34 -42 -52 -58 -63 -60 -43 -25
Total Gross Profit		 116 128 120 116 105 101 95 92 93 100 101
Total Revenue		 155 161 155 150 139 134 127 126 122 128 131
Operating Revenue		 155 161 155 150 139 134 127 126 122 128 131
Total Cost of Revenue		 39 33 35 35 34 33 32 34 30 29 30
Operating Cost of Revenue		 39 33 35 35 34 33 32 34 30 29 30
Total Operating Expenses		 154 191 152 149 146 153 153 155 153 143 126
Selling, General & Admin Expense		 45 72 40 38 40 39 42 41 42 38 33
Marketing Expense		 56 67 60 57 55 59 58 58 51 50 41
Research & Development Expense		 54 51 52 55 52 54 54 55 60 55 52
Total Other Income / (Expense), net		 7.57 8.10 11 11 9.88 13 10 8.76 9.17 10 1.19
Interest & Investment Income		 7.57 8.10 11 11 9.88 13 10 8.76 9.17 - -
Income Tax Expense		 4.02 11 8.99 11 7.12 8.55 1.26 3.51 1.98 4.75 3.16
Basic Earnings per Share		 ($0.31) ($0.61) ($0.28) ($0.31) ($0.36) ($0.45) ($0.46) ($0.54) ($0.50) ($0.36) ($0.25)
Weighted Average Basic Shares Outstanding		 110.28M 107.83M 108.25M 107.70M 107.27M 106.39M 106.77M 106.29M 105.67M 104.66M 104.88M
Diluted Earnings per Share		 ($0.31) ($0.61) ($0.28) ($0.31) ($0.36) ($0.45) ($0.46) ($0.54) ($0.50) ($0.36) ($0.25)
Weighted Average Diluted Shares Outstanding		 110.28M 107.83M 108.25M 107.70M 107.27M 106.39M 106.77M 106.29M 105.67M 104.66M 104.88M
Weighted Average Basic & Diluted Shares Outstanding		 111.49M 109.92M 108.20M 108.22M 107.61M 107.09M 106.86M 106.62M 106.21M 105.46M 104.95M

Annual Cash Flow Statements for NovoCure

This table details how cash moves in and out of NovoCure's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Change in Cash & Equivalents		 -76 127 -94 -37 67 37 62 -19 -19 62 -118
Net Cash From Operating Activities		 -26 -73 31 83 99 27 -1.87 -33 -108 -100 -74
Net Cash From Continuing Operating Activities		 -26 -73 31 83 99 27 -1.87 -33 -108 -100 -74
Net Income / (Loss) Continuing Operations		 -169 -207 -93 -58 20 -7.23 -64 -62 -132 -112 -81
Consolidated Net Income / (Loss)		 -169 -207 -93 -58 20 -7.23 -64 -62 -132 -112 -81
Depreciation Expense		 11 11 11 10 9.15 8.46 9.01 7.68 5.65 3.15 1.96
Amortization Expense		 -26 -23 -1.54 3.10 3.26 -2.18 1.02 0.25 0.16 0.33 -0.02
Non-Cash Adjustments To Reconcile Net Income		 135 146 107 104 75 52 40 27 28 6.82 3.46
Changes in Operating Assets and Liabilities, net		 22 0.15 7.03 24 -8.52 -24 11 -6.76 -9.68 1.40 1.04
Net Cash From Investing Activities		 -140 184 -140 -145 -473 -52 -5.49 8.63 13 -115 -46
Net Cash From Continuing Investing Activities		 -140 184 -140 -145 -473 -52 -5.49 8.63 13 -115 -46
Purchase of Property, Plant & Equipment		 -43 -27 -21 -24 -15 -10 -6.71 -7.37 -5.67 -4.67 -0.85
Purchase of Investments		 -875 -1,004 -1,298 -1,079 -608 -462 -254 -104 -239 -209 -138
Sale and/or Maturity of Investments		 778 1,215 1,179 958 150 421 255 120 270 104 93
Net Cash From Financing Activities		 90 16 15 26 440 62 69 5.17 75 277 2.15
Net Cash From Continuing Financing Activities		 90 16 15 26 440 62 69 5.17 75 277 2.15
Repayment of Debt		 -13 -0.01 -0.03 -0.03 -150 - -100 -0.08 - - -0.06
Issuance of Debt		 97 0.00 0.00 0.00 558 -0.03 149 0.02 73 23 0.05
Issuance of Common Equity		 4.15 4.42 5.22 4.55 3.37 2.47 1.84 1.54 0.62 254 2.15
Other Financing Activities, net		 2.16 11 10 21 28 59 18 3.69 1.69 - -
Effect of Exchange Rate Changes		 -0.17 0.13 -0.10 -0.19 0.25 0.03 - - - - -
Cash Interest Paid		 7.71 0.01 0.04 0.10 8.69 14 13 10 6.60 1.69 0.03
Cash Income Taxes Paid		 23 14 5.48 3.11 -3.26 11 20 10 9.45 1.49 0.28

Quarterly Cash Flow Statements for NovoCure

This table details how cash moves in and out of NovoCure's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -37 -23 21 -289 215 86 -0.98 -29 71 -128 -124
Net Cash From Operating Activities		 -36 -3.45 10 -1.72 -32 -15 -19 -23 -17 -3.71 22
Net Cash From Continuing Operating Activities		 -36 -3.45 10 -1.72 -32 -15 -19 -23 -17 -3.71 22
Net Income / (Loss) Continuing Operations		 -34 -66 -31 -33 -39 -47 -49 -57 -53 -37 -27
Consolidated Net Income / (Loss)		 -34 -66 -31 -33 -39 -47 -49 -57 -53 -37 -27
Depreciation Expense		 3.33 3.10 2.46 2.86 2.82 2.72 2.80 2.72 2.72 2.70 2.66
Amortization Expense		 -6.65 -6.67 -6.74 -6.85 -5.38 -7.26 -6.69 -5.08 -4.06 -3.28 0.23
Non-Cash Adjustments To Reconcile Net Income		 23 45 37 22 32 21 30 41 54 28 26
Changes in Operating Assets and Liabilities, net		 -21 21 8.50 14 -22 16 3.56 -3.70 -16 5.71 20
Net Cash From Investing Activities		 -6.47 -22 10 -374 246 99 17 -14 82 -128 -150
Net Cash From Continuing Investing Activities		 -6.47 -22 10 -374 246 99 17 -14 82 -128 -150
Purchase of Property, Plant & Equipment		 -11 -8.94 -11 -11 -12 -6.82 -7.25 -6.93 -6.09 -6.43 -5.70
Purchase of Investments		 -116 -183 -169 -523 0.00 -193 -251 -322 -238 -226 -503
Sale and/or Maturity of Investments		 120 170 190 160 258 299 276 315 326 105 359
Net Cash From Financing Activities		 5.25 2.69 0.10 87 0.21 1.91 1.17 7.50 5.20 3.41 4.20
Net Cash From Continuing Financing Activities		 5.25 2.69 0.10 87 0.21 1.91 1.17 7.50 5.20 3.41 4.20
Repayment of Debt		 0.00 - - -13 0.00 - - -0.00 -0.01 -0.01 -0.01
Issuance of Debt		 0.00 - - - - - - - - - -
Issuance of Common Equity		 0.00 1.96 - 2.19 0.00 1.53 - 2.88 0.00 2.47 -
Other Financing Activities, net		 5.25 0.72 0.10 1.12 0.21 0.38 1.17 4.62 5.21 0.95 4.21
Effect of Exchange Rate Changes		 0.23 -0.13 0.09 -0.08 -0.06 0.20 -0.10 -0.01 0.04 0.16 -0.11
Cash Interest Paid		 2.65 2.78 2.96 1.97 0.00 0.01 - - 0.00 0.04 0.00
Cash Income Taxes Paid		 4.97 6.41 6.64 7.50 2.91 4.92 1.20 5.83 1.71 1.55 0.91

Annual Balance Sheets for NovoCure

This table presents NovoCure's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Total Assets		 1,241 1,146 1,192 1,139 1,052 479 340 265 282 307 118
Total Current Assets		 1,107 1,034 1,112 1,074 999 440 321 245 262 294 112
Cash & Equivalents		 164 241 115 209 235 177 141 79 100 119 58
Restricted Cash		 2.33 1.74 0.51 0.81 11 2.10 2.13 2.13 0.27 0.09 0.06
Short-Term Investments		 796 670 854 729 608 149 105 105 120 150 45
Accounts Receivable		 74 61 86 94 97 59 37 30 6.34 0.00 -
Inventories, net		 35 38 29 24 27 24 23 22 26 14 3.45
Other Current Assets		 35 23 26 17 21 29 14 8.11 10 11 5.71
Plant, Property, & Equipment, net		 78 51 33 23 11 9.34 8.44 9.03 9.81 6.55 3.73
Total Noncurrent Assets		 57 60 47 43 41 30 9.98 11 10 6.88 2.31
Other Noncurrent Operating Assets		 57 60 47 43 41 30 9.98 11 10 6.88 2.31
Total Liabilities & Shareholders' Equity		 1,241 1,146 1,192 1,139 1,052 479 340 265 282 307 118
Total Liabilities		 881 784 750 729 575 262 228 152 140 57 20
Total Current Liabilities		 756 179 159 143 114 86 65 50 37 29 18
Short-Term Debt		 558 0.00 - - - - - - - - -
Accounts Payable		 105 94 85 73 54 86 65 50 37 29 18
Accrued Expenses		 93 85 74 70 60 - - - - - -
Total Noncurrent Liabilities		 124 605 592 586 462 175 163 102 103 28 2.33
Long-Term Debt		 97 569 566 562 430 149 149 97 96 23 0.00
Noncurrent Employee Benefit Liabilities		 6.94 8.26 4.40 4.54 5.17 3.75 2.68 2.45 2.59 2.06 0.25
Other Noncurrent Operating Liabilities		 20 27 19 0.17 0.34 0.22 1.09 1.74 4.03 2.74 2.09
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 360 362 441 410 477 218 112 114 142 251 98
Total Preferred & Common Equity		 360 362 441 410 477 218 112 114 142 251 98
Total Common Equity		 360 362 441 410 477 218 112 114 142 251 98
Common Stock		 1,520 1,353 1,222 1,100 1,111 871 757 697 664 640 374
Retained Earnings		 -1,154 -986 -778 -686 -631 -651 -644 -582 -520 -388 -277
Accumulated Other Comprehensive Income / (Loss)		 -5.50 -5.47 -2.43 -3.17 -3.83 -2.77 -1.40 -1.34 -1.88 -1.51 0.00

Quarterly Balance Sheets for NovoCure

This table presents NovoCure's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 1,249 1,222 1,212 1,121 1,146 1,159 1,174 1,174
Total Current Assets		 1,089 1,095 1,093 1,003 1,048 1,065 1,089 1,102
Cash & Equivalents		 127 185 165 454 155 157 186 244
Restricted Cash		 2.15 3.78 3.65 3.60 1.65 0.52 0.68 0.23
Short-Term Investments		 802 774 786 416 766 784 772 727
Accounts Receivable		 85 67 65 65 65 71 75 88
Inventories, net		 39 39 40 42 37 33 32 27
Other Current Assets		 34 25 33 21 23 20 - 17
Plant, Property, & Equipment, net		 80 73 66 59 46 41 36 30
Total Noncurrent Assets		 80 53 53 60 53 52 49 42
Other Noncurrent Operating Assets		 80 53 53 60 53 52 49 42
Total Liabilities & Shareholders' Equity		 1,249 1,222 1,212 1,121 1,146 1,159 1,174 1,174
Total Liabilities		 887 861 850 762 753 743 742 729
Total Current Liabilities		 743 735 169 160 157 150 149 141
Short-Term Debt		 559 557 - - - - - -
Accounts Payable		 95 91 90 84 80 83 81 77
Accrued Expenses		 89 86 79 76 77 68 67 64
Total Noncurrent Liabilities		 144 126 681 602 595 593 593 588
Long-Term Debt		 97 97 653 570 568 567 566 565
Noncurrent Employee Benefit Liabilities		 5.77 7.89 6.02 6.57 5.37 4.84 5.14 4.09
Other Noncurrent Operating Liabilities		 40 21 22 26 22 20 20 15
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 362 361 362 359 394 416 432 445
Total Preferred & Common Equity		 362 361 362 359 394 416 432 445
Total Common Equity		 362 361 362 359 394 416 432 445
Common Stock		 1,555 1,454 1,423 1,388 1,334 1,307 1,266 1,189
Retained Earnings		 -1,188 -1,088 -1,058 -1,024 -938 -889 -832 -741
Accumulated Other Comprehensive Income / (Loss)		 -4.20 -5.38 -3.52 -4.15 -1.99 -1.98 -2.69 -2.31

Annual Metrics And Ratios for NovoCure

This table displays calculated financial ratios and metrics derived from NovoCure's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 18.82% -5.30% 0.53% 8.23% 40.72% 41.62% 40.13% 113.57% 150.52% 113.60% 49.53%
EBITDA Growth		 24.52% -204.58% -159.63% -172.37% 697.23% 122.71% 24.70% 71.33% -8.95% -28.51% -35.29%
EBIT Growth		 26.78% -160.12% -101.93% -245.83% 3,426.15% 97.29% 14.38% 65.90% -10.89% -29.74% -24.35%
NOPAT Growth		 26.78% -160.12% -101.93% -193.29% 5,299.45% 97.29% 14.38% 65.90% -10.89% -29.74% -24.35%
Net Income Growth		 18.55% -123.75% -58.58% -394.58% 373.97% 88.62% -3.08% 53.23% -18.16% -38.30% -4.28%
EPS Growth		 20.00% -121.59% -57.14% -411.11% 357.14% 89.86% 1.43% 54.55% 58.04% 43.19% 4.01%
Operating Cash Flow Growth		 64.04% -338.20% -62.80% -16.53% 272.46% 1,527.35% 94.37% 69.20% -7.72% -34.53% -40.84%
Free Cash Flow Firm Growth		 -5.93% -178.14% -350.72% -158.55% 149.10% -246.87% 66.16% 63.87% -15.84% -59.81% 0.00%
Invested Capital Growth		 181.87% -48.41% -22.15% -29.18% 25.35% 293.41% -46.94% 36.38% 323.85% 191.83% 0.00%
Revenue Q/Q Growth		 4.76% 1.06% -0.88% -1.97% 9.95% 9.19% 6.90% 15.25% 27.46% 0.00% 0.00%
EBITDA Q/Q Growth		 -6.09% -5.47% -41.56% -516.36% 61.62% 244.16% -24.23% 30.58% 10.76% 0.00% 0.00%
EBIT Q/Q Growth		 -7.29% -3.90% -27.99% -401.33% 64.67% 90.61% -14.09% 25.37% 9.94% 0.00% 0.00%
NOPAT Q/Q Growth		 -7.29% -3.90% -27.99% -401.33% -27.69% 90.61% -14.09% 25.37% 9.94% 0.00% 0.00%
Net Income Q/Q Growth		 -12.58% -4.96% -13.28% -116.31% 3.43% 73.34% -7.96% 15.40% 7.55% 0.00% 0.00%
EPS Q/Q Growth		 -11.43% -4.84% -14.29% -100.00% -10.00% 75.00% -6.15% 15.66% -222.22% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 29.64% -17.37% -37.04% -32.07% 88.39% -27.01% 91.36% 24.63% 10.33% -9.31% 0.00%
Free Cash Flow Firm Q/Q Growth		 -24.02% 7.00% -7.49% -145.33% 3,227.03% -1,752.54% 61.12% 20.81% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 3.59% -51.12% -7.04% 18.26% -6.99% 112.54% -60.56% 1.68% 0.43% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 77.33% 74.81% 78.64% 78.53% 78.46% 74.78% 67.73% 68.59% 44.16% 37.71% 35.21%
EBITDA Margin		 -30.55% -48.10% -14.96% -5.79% 8.66% 1.53% -9.53% -17.74% -132.12% -303.79% -504.93%
Operating Margin		 -28.17% -45.72% -16.64% -8.29% 6.15% -0.26% -13.57% -22.22% -139.12% -314.31% -517.47%
EBIT Margin		 -28.17% -45.72% -16.64% -8.29% 6.15% -0.26% -13.57% -22.22% -139.12% -314.31% -517.47%
Profit (Net Income) Margin		 -27.86% -40.65% -17.20% -10.91% 4.01% -2.06% -25.62% -34.83% -159.06% -337.24% -520.87%
Tax Burden Percent		 128.56% 107.98% 113.06% 112.05% 109.42% 81.94% 138.35% 127.15% 108.55% 104.14% 100.48%
Interest Burden Percent		 76.93% 82.34% 91.42% 117.46% 59.54% 965.43% 136.44% 123.31% 105.33% 103.03% 100.18%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% -9.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -329.70% -585.26% -149.30% -54.52% 55.53% -1.92% -120.92% -124.73% -699.47% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -314.54% -573.48% -141.52% -47.45% 60.21% 3.09% -78.12% -92.49% -671.84% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 283.03% 533.73% 127.57% 41.36% -49.82% -2.46% 64.63% 76.54% 632.40% 0.00% 0.00%
Return on Equity (ROE)		 -46.67% -51.52% -21.73% -13.16% 5.71% -4.38% -56.29% -48.19% -67.07% -64.00% -82.43%
Cash Return on Invested Capital (CROIC)		 -424.95% -521.40% -124.39% -20.35% 33.03% -120.85% -59.60% -155.51% -823.11% -1,861.13% 0.00%
Operating Return on Assets (OROA)		 -14.29% -19.92% -7.68% -4.05% 3.97% -0.22% -11.13% -14.37% -39.13% -48.91% -68.00%
Return on Assets (ROA)		 -14.13% -17.71% -7.94% -5.33% 2.59% -1.77% -21.01% -22.53% -44.74% -52.48% -68.45%
Return on Common Equity (ROCE)		 -46.67% -51.52% -21.73% -13.16% 5.71% -4.38% -56.29% -48.19% -67.07% -64.00% -82.43%
Return on Equity Simple (ROE_SIMPLE)		 -46.82% -57.12% -20.97% -14.21% 4.16% -3.32% -56.62% -54.30% -92.62% -44.49% -82.43%
Net Operating Profit after Tax (NOPAT)		 -119 -163 -63 -31 33 -0.64 -24 -28 -81 -73 -56
NOPAT Margin		 -19.72% -32.00% -11.65% -5.80% 6.73% -0.18% -9.50% -15.55% -97.39% -220.02% -362.23%
Net Nonoperating Expense Percent (NNEP)		 -15.16% -11.77% -7.78% -7.07% -4.69% -5.00% -42.81% -32.24% -27.63% -22.22% -47.87%
Return On Investment Capital (ROIC_SIMPLE)		 -11.75% -17.50% -6.23% - - - - - - - -
Cost of Revenue to Revenue		 22.67% 25.19% 21.36% 21.47% 21.54% 25.22% 32.27% 31.41% 55.84% 62.29% 64.79%
SG&A Expenses to Revenue		 31.37% 32.21% 24.68% 23.57% 21.73% 25.03% 29.61% 33.39% 61.54% 102.35% 155.27%
R&D to Revenue		 34.64% 43.79% 38.32% 37.62% 26.70% 22.49% 20.39% 21.52% 50.03% 132.22% 260.69%
Operating Expenses to Revenue		 105.50% 120.53% 95.29% 86.82% 72.31% 75.04% 81.31% 90.80% 183.29% 352.02% 552.68%
Earnings before Interest and Taxes (EBIT)		 -170 -233 -90 -44 30 -0.91 -34 -39 -115 -104 -80
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -185 -245 -80 -31 43 5.37 -24 -31 -110 -101 -78
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 8.95 4.40 17.45 18.99 36.97 38.29 27.74 15.90 4.79 7.45 0.00
Price to Tangible Book Value (P/TBV)		 8.95 4.40 17.45 18.99 36.97 38.29 27.74 15.90 4.79 7.45 0.00
Price to Revenue (P/Rev)		 5.33 3.13 14.31 14.57 35.63 23.74 12.55 10.20 8.22 56.51 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 889.29 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 54.60 66.03 198.49 157.45 258.15 153.76 223.11 67.42 29.86 368.43 0.00
Enterprise Value to Revenue (EV/Rev)		 4.82 2.46 13.56 13.89 34.80 23.27 12.16 9.70 6.73 49.06 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 401.89 1,522.43 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 565.94 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 517.20 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 236.90 89.80 173.53 307.12 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 869.56 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.82 1.57 1.28 1.40 0.93 0.75 1.33 0.86 0.68 0.09 0.00
Long-Term Debt to Equity		 0.27 1.57 1.28 1.40 0.93 0.75 1.33 0.86 0.68 0.09 0.00
Financial Leverage		 -0.90 -0.93 -0.90 -0.87 -0.83 -0.80 -0.83 -0.83 -0.94 -1.00 -1.05
Leverage Ratio		 3.30 2.91 2.74 2.47 2.21 2.48 2.68 2.14 1.50 1.22 1.20
Compound Leverage Factor		 2.54 2.40 2.50 2.90 1.31 23.96 3.66 2.64 1.58 1.26 1.21
Debt to Total Capital		 64.54% 61.08% 56.18% 58.36% 48.24% 42.89% 57.08% 46.15% 40.34% 8.43% 0.00%
Short-Term Debt to Total Capital		 54.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 9.58% 61.08% 56.18% 58.36% 48.24% 42.89% 57.08% 46.15% 40.34% 8.43% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 35.46% 38.92% 43.82% 41.64% 51.76% 57.11% 42.92% 53.85% 59.66% 91.57% 100.00%
Debt to EBITDA		 -3.54 -2.32 -7.03 -18.57 10.38 30.46 -6.31 -3.10 -0.88 -0.23 0.00
Net Debt to EBITDA		 1.66 1.40 5.03 11.73 -9.57 -30.66 4.18 2.81 1.13 2.45 0.00
Long-Term Debt to EBITDA		 -0.53 -2.32 -7.03 -18.57 10.38 30.46 -6.31 -3.10 -0.88 -0.23 0.00
Debt to NOPAT		 -5.49 -3.49 -9.02 -18.54 13.35 -255.65 -6.33 -3.54 -1.19 -0.32 0.00
Net Debt to NOPAT		 2.57 2.11 6.45 11.71 -12.32 257.30 4.19 3.20 1.53 3.38 0.00
Long-Term Debt to NOPAT		 -0.82 -3.49 -9.02 -18.54 13.35 -255.65 -6.33 -3.54 -1.19 -0.32 0.00
Altman Z-Score		 1.27 0.69 6.40 6.89 19.10 18.84 6.87 5.13 0.25 18.11 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.46 5.78 7.00 7.53 8.80 5.10 4.98 4.88 7.10 10.27 6.33
Quick Ratio		 1.37 5.43 6.65 7.23 8.27 4.46 4.37 4.24 6.13 9.41 5.81
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -154 -145 -52 -12 20 -40 -12 -34 -95 -82 -51
Operating Cash Flow to CapEx		 -61.53% -270.68% 144.15% 342.39% 662.40% 253.89% -27.79% -449.82% -1,896.56% -2,140.22% -8,744.88%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -5.09 -0.95 -3.74 -15.45 -26.02 -356.33
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 3.37 -0.15 -3.61 -17.50 -31.70 -515.58
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 2.04 -0.70 -4.42 -18.43 -33.18 -521.48
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.51 0.44 0.46 0.49 0.65 0.86 0.82 0.65 0.28 0.16 0.13
Accounts Receivable Turnover		 8.94 6.91 5.98 5.62 6.36 7.37 7.51 9.86 0.00 0.00 0.00
Inventory Turnover		 3.75 3.80 4.27 4.43 4.17 3.83 3.59 2.34 2.36 2.42 2.91
Fixed Asset Turnover		 9.37 12.10 19.43 31.39 47.68 39.51 28.39 18.79 10.13 6.43 4.15
Accounts Payable Turnover		 1.38 1.43 1.46 1.82 1.52 1.17 1.40 1.28 1.41 0.89 0.57
Days Sales Outstanding (DSO)		 40.84 52.84 61.02 64.90 57.43 49.55 48.62 37.02 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 97.43 96.07 85.48 82.37 87.60 95.27 101.64 156.13 154.35 150.89 125.33
Days Payable Outstanding (DPO)		 265.38 255.49 250.71 200.56 239.83 310.75 261.64 285.79 258.32 409.95 642.61
Cash Conversion Cycle (CCC)		 -127.10 -106.58 -104.21 -53.29 -94.80 -165.93 -111.39 -92.65 -103.97 -259.06 -517.28
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 53 19 37 47 67 53 14 25 19 4.41 -4.80
Invested Capital Turnover		 16.72 18.29 12.81 9.40 8.25 10.54 12.73 8.02 7.18 -168.81 -6.46
Increase / (Decrease) in Invested Capital		 34 -18 -10 -19 13 40 -12 6.79 14 9.20 -4.80
Enterprise Value (EV)		 2,918 1,252 7,294 7,431 17,205 8,175 3,015 1,717 558 1,623 0.00
Market Capitalization		 3,224 1,595 7,698 7,795 17,615 8,340 3,114 1,805 681 1,870 0.00
Book Value per Share		 $3.33 $3.39 $4.20 $3.95 $4.68 $2.20 $1.21 $1.27 $1.64 $3.00 $7.84
Tangible Book Value per Share		 $3.33 $3.39 $4.20 $3.95 $4.68 $2.20 $1.21 $1.27 $1.64 $3.00 $7.84
Total Capital		 1,016 931 1,007 986 921 381 262 211 239 274 98
Total Debt		 655 569 566 575 444 164 149 97 96 23 0.00
Total Long-Term Debt		 97 569 566 575 444 164 149 97 96 23 0.00
Net Debt		 -307 -344 -404 -363 -410 -165 -99 -88 -124 -246 -103
Capital Expenditures (CapEx)		 43 27 21 24 15 10 6.71 7.37 5.67 4.67 0.85
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -54 -57 -17 -7.58 32 25 8.80 9.50 5.09 -4.23 -8.51
Debt-free Net Working Capital (DFNWC)		 908 855 953 931 886 354 257 195 225 265 94
Net Working Capital (NWC)		 350 855 953 931 886 354 257 195 225 265 94
Net Nonoperating Expense (NNE)		 49 44 30 27 13 6.59 40 34 51 39 25
Net Nonoperating Obligations (NNO)		 -307 -344 -404 -363 -410 -165 -99 -88 -124 -246 -103
Total Depreciation and Amortization (D&A)		 -14 -12 9.09 13 12 6.28 10 7.93 5.81 3.48 1.94
Debt-free, Cash-free Net Working Capital to Revenue		 -8.90% -11.20% -3.19% -1.42% 6.42% 7.24% 3.55% 5.36% 6.14% -12.80% -54.95%
Debt-free Net Working Capital to Revenue		 150.09% 167.92% 177.14% 173.99% 179.18% 100.66% 103.52% 110.11% 271.44% 801.76% 607.88%
Net Working Capital to Revenue		 57.86% 167.92% 177.14% 173.99% 179.18% 100.66% 103.52% 110.11% 271.44% 801.76% 607.88%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.56) ($1.95) ($0.88) ($0.56) $0.20 ($0.07) ($0.69) ($0.70) ($1.54) ($3.67) ($6.46)
Adjusted Weighted Average Basic Shares Outstanding		 107.83M 106.39M 104.66M 103.43M 100.93M 99.64M 94.99M 89.88M 87.07M 84.43M 12.49M
Adjusted Diluted Earnings per Share		 ($1.56) ($1.95) ($0.88) ($0.56) $0.18 ($0.07) ($0.69) ($0.70) ($1.54) ($3.67) ($6.46)
Adjusted Weighted Average Diluted Shares Outstanding		 107.83M 106.39M 104.66M 103.43M 108.88M 99.64M 94.99M 89.88M 87.07M 84.43M 12.49M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.07) ($0.69) ($0.70) ($1.54) ($3.67) ($6.46)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 109.92M 107.09M 105.46M 104.42M 102.41M 97.24M 91.83M 88.55M 85.56M 30.40M 12.49M
Normalized Net Operating Profit after Tax (NOPAT)		 -119 -163 -63 -31 21 -0.64 -24 -28 -81 -73 -56
Normalized NOPAT Margin		 -19.72% -32.00% -11.65% -5.80% 4.30% -0.18% -9.50% -15.55% -97.39% -220.02% -362.23%
Pre Tax Income Margin		 -21.67% -37.64% -15.22% -9.73% 3.66% -2.51% -18.52% -27.40% -146.54% -323.83% -518.40%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -0.12 -2.74 -4.29 -18.76 -33.00 -556.64
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -0.08 -1.92 -3.00 -13.13 -23.10 -389.65
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -1.44 -3.29 -5.09 -19.68 -34.49 -562.53
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -1.41 -2.47 -3.81 -14.05 -24.58 -395.54
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for NovoCure

This table displays calculated financial ratios and metrics derived from NovoCure's official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 11.91% 20.54% 21.81% 19.28% 13.36% 4.17% -2.81% -10.52% -11.17% -3.59% -1.95%
EBITDA Growth		 6.56% -18.87% 41.46% 42.20% 28.41% -29.15% -186.08% -268.41% -2,575.20% -118.41% -331.53%
EBIT Growth		 8.80% -22.41% 44.90% 46.41% 31.09% -20.33% -136.66% -196.57% -7,375.06% -83.68% -187.78%
NOPAT Growth		 8.80% -22.41% 44.90% 46.41% 31.09% -20.33% -136.66% -196.57% -7,375.06% -83.68% -187.78%
Net Income Growth		 11.46% -40.02% 38.22% 41.87% 26.95% -26.21% -86.20% -139.16% -1,041.83% -40.99% -102.50%
EPS Growth		 13.89% -35.56% 39.13% 42.59% 28.00% -25.00% -84.00% -134.78% -1,150.00% -44.00% -92.31%
Operating Cash Flow Growth		 -12.96% 76.29% 153.72% 92.44% -88.76% -292.72% -186.15% -244.25% -353.68% -125.74% -8.11%
Free Cash Flow Firm Growth		 -30.91% -327.89% 11.92% -45.61% -174.82% 6.20% -137.70% -22.81% -56.00% -739.35% -165.39%
Invested Capital Growth		 57.61% 181.87% 32.99% 45.50% 38.99% -48.41% -1.86% -26.22% -39.50% -22.15% -0.96%
Revenue Q/Q Growth		 -3.89% 3.98% 3.15% 8.56% 3.53% 5.08% 1.01% 3.17% -4.86% -1.96% -7.01%
EBITDA Q/Q Growth		 38.40% -83.86% 3.21% 14.77% 21.63% 9.46% 4.43% -5.57% -41.38% -100.55% -23.07%
EBIT Q/Q Growth		 40.19% -97.26% 4.43% 19.12% 19.72% 11.21% 7.05% -4.00% -40.19% -74.63% -16.49%
NOPAT Q/Q Growth		 40.19% -97.26% 4.43% 19.12% 19.72% 11.21% 7.05% -4.00% -40.19% -74.63% -16.49%
Net Income Q/Q Growth		 47.94% -115.64% 8.40% 13.89% 17.67% 4.86% 13.82% -8.21% -42.24% -40.36% -10.70%
EPS Q/Q Growth		 49.18% -117.86% 9.68% 13.89% 20.00% 2.17% 14.81% -8.00% -38.89% -44.00% -8.70%
Operating Cash Flow Q/Q Growth		 -933.47% -133.26% 703.26% 94.55% -116.88% 24.62% 15.05% -35.93% -351.23% -116.53% 42.24%
Free Cash Flow Firm Q/Q Growth		 25.96% -123.45% 16.82% 4.88% -142.01% 54.00% -37.52% -79.52% 17.39% -16.55% 28.95%
Invested Capital Q/Q Growth		 62.98% 3.59% -14.57% 9.28% 191.47% -51.12% -6.53% 4.38% 8.20% -7.04% -29.73%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 75.15% 79.25% 77.19% 76.95% 75.68% 75.67% 74.79% 73.01% 75.76% 77.51% 77.29%
EBITDA Margin		 -26.58% -41.47% -23.45% -24.99% -31.83% -42.05% -48.80% -51.58% -50.40% -33.92% -16.58%
Operating Margin		 -24.43% -39.25% -20.69% -22.33% -29.98% -38.66% -45.75% -49.71% -49.31% -33.46% -18.79%
EBIT Margin		 -24.43% -39.25% -20.69% -22.33% -29.98% -38.66% -45.75% -49.71% -49.31% -33.46% -18.79%
Profit (Net Income) Margin		 -22.14% -40.88% -19.71% -22.20% -27.99% -35.19% -38.87% -45.55% -43.43% -29.05% -20.29%
Tax Burden Percent		 113.28% 119.41% 141.63% 146.84% 122.50% 122.18% 102.62% 106.52% 103.88% 114.57% 113.49%
Interest Burden Percent		 80.01% 87.21% 67.26% 67.69% 76.21% 74.51% 82.79% 86.03% 84.78% 75.76% 95.15%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -149.37% -459.41% -185.18% -168.77% -232.18% -494.84% -412.14% -361.42% -341.97% -300.17% -179.66%
ROIC Less NNEP Spread (ROIC-NNEP)		 -146.67% -452.77% -182.74% -165.85% -229.39% -491.93% -409.85% -357.85% -339.11% -298.29% -177.26%
Return on Net Nonoperating Assets (RNNOA)		 117.73% 407.41% 160.85% 144.11% 201.85% 457.83% 371.60% 317.05% 297.90% 268.89% 160.86%
Return on Equity (ROE)		 -31.65% -52.00% -24.33% -24.66% -30.32% -37.01% -40.54% -44.37% -44.06% -31.28% -18.80%
Cash Return on Invested Capital (CROIC)		 -208.81% -424.95% -274.48% -291.35% -348.14% -521.40% -398.78% -242.65% -148.50% -124.39% -122.30%
Operating Return on Assets (OROA)		 -12.82% -19.91% -10.10% -10.36% -13.73% -16.84% -19.87% -21.74% -22.17% -15.44% -8.89%
Return on Assets (ROA)		 -11.62% -20.73% -9.62% -10.30% -12.82% -15.33% -16.88% -19.92% -19.52% -13.40% -9.59%
Return on Common Equity (ROCE)		 -31.65% -52.00% -24.33% -24.66% -30.32% -37.01% -40.54% -44.37% -44.06% -31.28% -18.80%
Return on Equity Simple (ROE_SIMPLE)		 -45.36% 0.00% -41.52% -46.63% -53.64% 0.00% -50.11% -41.94% -32.62% 0.00% -18.34%
Net Operating Profit after Tax (NOPAT)		 -27 -44 -22 -24 -29 -36 -41 -44 -42 -30 -17
NOPAT Margin		 -17.10% -27.48% -14.48% -15.63% -20.98% -27.06% -32.02% -34.80% -34.52% -23.43% -13.15%
Net Nonoperating Expense Percent (NNEP)		 -2.70% -6.65% -2.44% -2.92% -2.78% -2.91% -2.29% -3.57% -2.86% -1.88% -2.40%
Return On Investment Capital (ROIC_SIMPLE)		 -2.60% -4.36% - - - -3.89% - - - -2.99% -
Cost of Revenue to Revenue		 24.85% 20.75% 22.81% 23.05% 24.32% 24.33% 25.21% 26.99% 24.24% 22.49% 22.71%
SG&A Expenses to Revenue		 28.88% 44.95% 25.86% 25.08% 28.54% 29.49% 32.90% 32.35% 34.33% 29.64% 24.82%
R&D to Revenue		 34.70% 31.76% 33.45% 36.55% 37.25% 40.59% 42.12% 43.97% 48.86% 42.69% 39.66%
Operating Expenses to Revenue		 99.58% 118.50% 97.89% 99.29% 105.65% 114.32% 120.54% 122.72% 125.07% 110.97% 96.08%
Earnings before Interest and Taxes (EBIT)		 -38 -63 -32 -34 -42 -52 -58 -63 -60 -43 -25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -41 -67 -36 -38 -44 -56 -62 -65 -62 -44 -22
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.41 8.95 4.69 5.10 4.65 4.40 4.37 10.60 14.68 17.45 17.87
Price to Tangible Book Value (P/TBV)		 5.41 8.95 4.69 5.10 4.65 4.40 4.37 10.60 14.68 17.45 17.87
Price to Revenue (P/Rev)		 3.15 5.33 2.93 3.35 3.18 3.13 3.42 8.68 12.14 14.31 14.67
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 19.33 54.60 26.79 25.54 24.72 66.03 35.24 97.19 149.64 198.49 191.06
Enterprise Value to Revenue (EV/Rev)		 2.71 4.82 2.39 2.80 2.60 2.46 2.71 7.95 11.39 13.56 13.92
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 335.23 236.90 154.44
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.81 1.82 1.81 1.81 1.59 1.57 1.44 1.36 1.31 1.28 1.27
Long-Term Debt to Equity		 0.27 0.27 0.27 1.81 1.59 1.57 1.44 1.36 1.31 1.28 1.27
Financial Leverage		 -0.80 -0.90 -0.88 -0.87 -0.88 -0.93 -0.91 -0.89 -0.88 -0.90 -0.91
Leverage Ratio		 3.29 3.30 3.14 3.05 2.90 2.91 2.77 2.71 2.68 2.74 2.67
Compound Leverage Factor		 2.63 2.88 2.11 2.06 2.21 2.17 2.29 2.33 2.27 2.07 2.54
Debt to Total Capital		 64.46% 64.54% 64.46% 64.37% 61.32% 61.08% 59.06% 57.71% 56.72% 56.18% 55.90%
Short-Term Debt to Total Capital		 54.89% 54.96% 54.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 9.57% 9.58% 9.57% 64.37% 61.32% 61.08% 59.06% 57.71% 56.72% 56.18% 55.90%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 35.54% 35.46% 35.54% 35.63% 38.68% 38.92% 40.94% 42.29% 43.28% 43.82% 44.10%
Debt to EBITDA		 -3.61 -3.54 -3.76 -3.27 -2.50 -2.32 -2.45 -2.96 -3.92 -7.03 -9.94
Net Debt to EBITDA		 1.51 1.66 1.77 1.51 1.34 1.40 1.53 1.95 2.72 5.03 7.14
Long-Term Debt to EBITDA		 -0.54 -0.53 -0.56 -3.27 -2.50 -2.32 -2.45 -2.96 -3.92 -7.03 -9.94
Debt to NOPAT		 -5.62 -5.49 -5.88 -5.04 -3.80 -3.49 -3.62 -4.25 -5.43 -9.02 -11.53
Net Debt to NOPAT		 2.35 2.57 2.78 2.33 2.03 2.11 2.26 2.81 3.76 6.45 8.29
Long-Term Debt to NOPAT		 -0.83 -0.82 -0.87 -5.04 -3.80 -3.49 -3.62 -4.25 -5.43 -9.02 -11.53
Altman Z-Score		 0.72 1.55 0.67 1.36 1.28 1.21 1.43 3.69 5.37 6.53 7.04
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.47 1.46 1.49 6.46 6.26 5.78 6.67 7.10 7.32 7.00 7.81
Quick Ratio		 1.36 1.37 1.40 6.00 5.84 5.43 6.28 6.74 6.94 6.65 7.50
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -58 -79 -35 -42 -45 -18 -40 -29 -16 -20 -17
Operating Cash Flow to CapEx		 -336.11% -38.59% 97.13% -15.03% -267.94% -213.43% -266.29% -328.05% -274.75% -57.64% 393.13%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.52 0.51 0.49 0.46 0.46 0.44 0.43 0.44 0.45 0.46 0.47
Accounts Receivable Turnover		 8.31 8.94 8.74 8.11 7.51 6.91 6.60 6.02 5.94 5.98 5.97
Inventory Turnover		 3.47 3.75 3.59 3.62 3.57 3.80 3.92 3.91 3.84 4.27 4.68
Fixed Asset Turnover		 8.98 9.37 9.73 10.22 11.02 12.10 13.38 14.99 16.98 19.43 26.19
Accounts Payable Turnover		 1.58 1.38 1.59 1.54 1.60 1.43 1.59 1.51 1.55 1.46 1.69
Days Sales Outstanding (DSO)		 43.91 40.84 41.76 45.03 48.58 52.84 55.29 60.59 61.41 61.02 61.10
Days Inventory Outstanding (DIO)		 105.20 97.43 101.65 100.81 102.19 96.07 93.14 93.37 95.05 85.48 78.00
Days Payable Outstanding (DPO)		 230.55 265.38 228.99 237.00 228.60 255.49 229.49 242.47 235.49 250.71 216.21
Cash Conversion Cycle (CCC)		 -81.44 -127.10 -85.58 -91.16 -77.82 -106.58 -81.05 -88.51 -79.04 -104.21 -77.11
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 87 53 52 60 55 19 39 42 40 37 40
Invested Capital Turnover		 8.73 16.72 12.78 10.80 11.06 18.29 12.87 10.39 9.91 12.81 13.66
Increase / (Decrease) in Invested Capital		 32 34 13 19 16 -18 -0.74 -15 -26 -10 -0.39
Enterprise Value (EV)		 1,684 2,918 1,382 1,542 1,366 1,252 1,367 4,034 5,950 7,294 7,552
Market Capitalization		 1,959 3,224 1,691 1,843 1,670 1,595 1,722 4,408 6,342 7,698 7,958
Book Value per Share		 $3.29 $3.33 $3.33 $3.36 $3.35 $3.39 $3.69 $3.91 $4.10 $4.20 $4.25
Tangible Book Value per Share		 $3.29 $3.33 $3.33 $3.36 $3.35 $3.39 $3.69 $3.91 $4.10 $4.20 $4.25
Total Capital		 1,018 1,016 1,015 1,015 929 931 962 983 998 1,007 1,010
Total Debt		 656 655 654 653 570 569 568 567 566 566 565
Total Long-Term Debt		 97 97 97 653 570 569 568 567 566 566 565
Net Debt		 -275 -307 -309 -301 -304 -344 -355 -374 -392 -404 -406
Capital Expenditures (CapEx)		 11 8.94 11 11 12 6.82 7.25 6.93 6.09 6.43 5.70
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -26 -54 -46 -31 -31 -57 -32 -26 -18 -17 -9.25
Debt-free Net Working Capital (DFNWC)		 905 908 918 924 842 855 891 915 940 953 961
Net Working Capital (NWC)		 346 350 360 924 842 855 891 915 940 953 961
Net Nonoperating Expense (NNE)		 7.81 22 8.11 9.87 9.70 11 8.71 14 11 7.22 9.35
Net Nonoperating Obligations (NNO)		 -275 -307 -309 -301 -304 -344 -355 -374 -392 -404 -406
Total Depreciation and Amortization (D&A)		 -3.33 -3.57 -4.28 -4.00 -2.57 -4.54 -3.89 -2.35 -1.33 -0.58 2.89
Debt-free, Cash-free Net Working Capital to Revenue		 -4.23% -8.90% -7.98% -5.67% -5.95% -11.20% -6.36% -5.11% -3.54% -3.19% -1.71%
Debt-free Net Working Capital to Revenue		 145.56% 150.09% 158.83% 167.95% 160.27% 167.92% 176.76% 180.32% 179.95% 177.14% 177.16%
Net Working Capital to Revenue		 55.65% 57.86% 62.36% 167.95% 160.27% 167.92% 176.76% 180.32% 179.95% 177.14% 177.16%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.31) ($0.61) ($0.28) ($0.31) ($0.36) ($0.45) ($0.46) ($0.54) ($0.50) ($0.36) ($0.25)
Adjusted Weighted Average Basic Shares Outstanding		 110.28M 107.83M 108.25M 107.70M 107.27M 106.39M 106.77M 106.29M 105.67M 104.66M 104.88M
Adjusted Diluted Earnings per Share		 ($0.31) ($0.61) ($0.28) ($0.31) ($0.36) ($0.45) ($0.46) ($0.54) ($0.50) ($0.36) ($0.25)
Adjusted Weighted Average Diluted Shares Outstanding		 110.28M 107.83M 108.25M 107.70M 107.27M 106.39M 106.77M 106.29M 105.67M 104.66M 104.88M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 111.49M 109.92M 108.20M 108.22M 107.61M 107.09M 106.86M 106.62M 106.21M 105.46M 104.95M
Normalized Net Operating Profit after Tax (NOPAT)		 -27 -44 -22 -24 -29 -36 -41 -44 -42 -30 -17
Normalized NOPAT Margin		 -17.10% -27.48% -14.48% -15.63% -20.98% -27.06% -32.02% -34.80% -34.52% -23.43% -13.15%
Pre Tax Income Margin		 -19.55% -34.23% -13.92% -15.12% -22.85% -28.80% -37.87% -42.76% -41.81% -25.35% -17.88%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About NovoCure's Financials

When does NovoCure's financial year end?

According to the most recent income statement we have on file, NovoCure's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has NovoCure's net income changed over the last 10 years?

NovoCure's net income appears to be on an upward trend, with a most recent value of -$168.63 million in 2024, rising from -$80.68 million in 2014. The previous period was -$207.04 million in 2023. Check out NovoCure's forecast to explore projected trends and price targets.

What is NovoCure's operating income?
NovoCure's total operating income in 2024 was -$170.50 million, based on the following breakdown:
  • Total Gross Profit: $468.04 million
  • Total Operating Expenses: $638.54 million
How has NovoCure revenue changed over the last 10 years?

Over the last 10 years, NovoCure's total revenue changed from $15.49 million in 2014 to $605.22 million in 2024, a change of 3,807.2%.

How much debt does NovoCure have?

NovoCure's total liabilities were at $880.61 million at the end of 2024, a 12.4% increase from 2023, and a 4,302.8% increase since 2014.

How much cash does NovoCure have?

In the past 10 years, NovoCure's cash and equivalents has ranged from $57.61 million in 2014 to $240.82 million in 2023, and is currently $163.77 million as of their latest financial filing in 2024.

How has NovoCure's book value per share changed over the last 10 years?

Over the last 10 years, NovoCure's book value per share changed from 7.84 in 2014 to 3.33 in 2024, a change of -57.5%.


Related Companies

This page (NASDAQ:NVCR) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored